ASCO 2021: Can We Define the Standard of Therapy for First-Line Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)?

(UroToday.com) In this summary of the preceding three presentations, Dr. Lisa Horvath showed where each abstract falls within the natural history of prostate cancer.